The company, located in Israel, holds a worldwide exclusive license for developing and manufacturing the Universal Flu Vaccine based on 20 years of research by Professor Ruth Arnon. BiondVax has conducted multiple clinical trials, including a Phase 3 trial with over 12,000 participants, and has built a state-of-the-art manufacturing facility. Their vaccine, M-001, is designed to provide long-lasting protection against multiple strains of the influenza virus, offering a significant advancement over existing vaccines.